RT Journal Article
SR Electronic
T1 SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.11.21256972
DO 10.1101/2021.05.11.21256972
A1 Jéromine Klingler
A1 Gregory S. Lambert
A1 Vincenza Itri
A1 Sean Liu
A1 Juan C. Bandres
A1 Gospel Enyindah-Asonye
A1 Xiaomei Liu
A1 Kasopefoluwa Y. Oguntuyo
A1 Fatima Amanat
A1 Benhur Lee
A1 Susan Zolla-Pazner
A1 Chitra Upadhyay
A1 Catarina E. Hioe
YR 2021
UL http://medrxiv.org/content/early/2021/05/17/2021.05.11.21256972.abstract
AB Background Mass vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on-going in the United States with vaccines approved for emergency use by the FDA. Each vaccine can induce spike-specific antibodies (Abs) with virus-neutralizing activities; however, the Fc-mediated Ab activities have received little attention. Moreover, while plasma/serum Abs are commonly studied, scant information is available about Abs in the respiratory mucosa, the site of SARS-CoV-2 transmission.Methods Plasma and saliva were collected from mRNA vaccine recipients and convalescent coronavirus disease 2019 (COVID-19) patients. Antigen-specific total Ig and Ig isotypes were measured. In addition to virus neutralization, Fc-mediated activities were investigated, including antibody-dependent cellular phagocytosis (ADCP) and complement deposition.Results Similar to infection, vaccination stimulated spike-specific Ab responses detected in plasma and saliva, with IgG1 as the dominant isotype. Interestingly, vaccination produced greater IgG2, IgG3, and IgG4 responses and higher ratios of (IgG1+IgG3)/(IgG2+IgG4) than infection. Moreover, while plasma neutralization and ADCP potencies were comparable in vaccinated and convalescent individuals, vaccine-induced plasma Abs elicited stronger complement binding and activation.Conclusion Compared with natural infection, mRNA vaccines induced a greater array of IgG subtypes against spike in saliva and plasma. The vaccine-induced Abs were also more potent in mediating complement activation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Department of Medicine of the Icahn School of Medicine at Mount Sinai Department of Medicine (to S.Z-P., C.E.H.); the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai (to B.L.), the Department of Veterans Affairs [Merit Review Grant I01BX003860] (to C.E.H.) and [Research Career Scientist Award 1IK6BX004607] (to C.E.H.); the National Institutes of Health [grant AI139290] to C.E.H., [grants R01 AI123449, R21 AI1498033] to B.L, [grant R01 AI140909] to C.U. G.E-A and K.Y.O. were supported by Viral-Host Pathogenesis Training Grant T32 AI07647. K.Y.O was also supported by Training Grant F31 AI154739.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB at the Icahn School of Medicine at Mount Sinai (IRB#17-00060, IRB#19-01243) and the James J. Peter Veterans Affairs Medical Center (IRB#BAN-1604)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data are available upon written request to the corresponding author.